159 related articles for article (PubMed ID: 31740230)
21. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
[TBL] [Abstract][Full Text] [Related]
22. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Parameters in Differentiated Thyroid Carcinomas.
Cipriani NA
Surg Pathol Clin; 2019 Dec; 12(4):883-900. PubMed ID: 31672296
[TBL] [Abstract][Full Text] [Related]
24. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
25. Molecular mutations as a possible factor for determining extent of thyroid surgery.
Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
[TBL] [Abstract][Full Text] [Related]
26. [Hobnail variant of papillary thyroid carcinoma].
Da Cruz V; Lopez J; Lifante JC; Decaussin-Petrucci M
Ann Pathol; 2021 Apr; 41(2):201-206. PubMed ID: 33272718
[TBL] [Abstract][Full Text] [Related]
27. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
28. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
29. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
[TBL] [Abstract][Full Text] [Related]
31. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
32. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
[TBL] [Abstract][Full Text] [Related]
33. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
Adeniran AJ; Zhu Z; Gandhi M; Steward DL; Fidler JP; Giordano TJ; Biddinger PW; Nikiforov YE
Am J Surg Pathol; 2006 Feb; 30(2):216-22. PubMed ID: 16434896
[TBL] [Abstract][Full Text] [Related]
34. Metastatic hobnail variant of papillary thyroid carcinoma: A diagnostic challenge in cell block preparation.
Mohapatra D; Naik S; Das P; Agrawala S
Indian J Pathol Microbiol; 2021; 64(2):358-361. PubMed ID: 33851635
[TBL] [Abstract][Full Text] [Related]
35. Cytological and molecular features of papillary thyroid carcinoma with prominent hobnail features: a case report.
Bellevicine C; Cozzolino I; Malapelle U; Zeppa P; Troncone G
Acta Cytol; 2012; 56(5):560-4. PubMed ID: 23075900
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
37. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
38. Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Johnson DN; Sadow PM
Hum Pathol; 2018 Dec; 82():32-38. PubMed ID: 30146440
[TBL] [Abstract][Full Text] [Related]
39. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior.
Asioli S; Erickson LA; Righi A; Lloyd RV
Hum Pathol; 2013 Mar; 44(3):320-8. PubMed ID: 23036367
[TBL] [Abstract][Full Text] [Related]
40. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
